Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000893838-19-000020
Filing Date
2019-09-13
Accepted
2019-09-13 16:35:41
Documents
2

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13G DATED SEPTEMBER 13, 2019 mundipharma13g92019.htm SC 13G 78850
2 POWER OF ATTORNEY powerofattorney.htm EX-99.1 9443
  Complete submission text file 0000893838-19-000020.txt   89877
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Subject) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-88806 | Film No.: 191092954
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address ST. ALBAN-RHEINWEG 74 BASEL V8 4020
Business Address ST. ALBAN-RHEINWEG 74 BASEL V8 4020 41 61 205 11 11
Mundipharma AG (Filed by) CIK: 0001787709 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: SC 13G